39 results about "Occludin" patented technology

The invention provides thesium chinense polysaccharide as well as a preparation method and application thereof, compared with the prior art, neutral polysaccharide TP1 is efficiently extracted from thesium chinense by adopting a hot water extraction method, the neutral polysaccharide TP1 mainly comprises fructose, glucose and galactose according to a molar ratio of 44.7: 33.8: 17.9, and the molecular weight Mw of the TP1 measured by adopting a GPC-RI-MALS chromatographic method is 5377Da. The invention also researches the protective effect of thesium chinense polysaccharide on DSS-induced colitis. The TP1 reduces the loss of intestinal tight junction proteins (Claudin-1, Occludin and ZO-1), regulates the abundance of bacteria in the intestinal tract and enriches bacteria (ruminococcus, lactobacillus and bifidobacterium) capable of generating SCFAs, in addition, the TP1 increases the expression of GPR41 and GPR43 receptors in colon tissues, and the symptoms of colitis are relieved by reducing oxidative stress and inflammatory cytokine levels through the GPR41 and GPR43 receptors mediated by the SCFAs. The thesium chinense polysaccharide TP1 prepared by the invention can be used for preparing medicines for preventing and treating colitis and also can be used for preparing food.

The invention discloses a probiotic which is derived from human milk and has the effects of resisting oxidation, resisting inflammation, protecting tissues and protecting intestinal barriers and application of the probiotic. Lactobacillus paracasei DPUMW-M14-9 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CCTCC M 20252990. The strain has the characteristics of acid resistance, bile resistance, strong oxidation resistance, high surface hydrophobicity, self-aggregation capability and the like. The lactobacillus paracasei DPUMW-M14-9 can effectively adhere to epithelial cells, promote cell proliferation and regulate and control the process of a cell cycle. The bacterial strain can be used for inhibiting proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) induced by lipopolysaccharide (LPS) and repairing tight junction proteins (ZO-1, Occludin and Claudin-1) at the same time, so that the integrity of epithelial cells is enhanced.

The invention discloses recombinant lactobacillus casei for expressing sialyltransferase ST6GALNAC1, and belongs to the technical field of genetic engineering and microorganisms. The recombinant bacterium is obtained by cloning an ST6GALNAC1 gene to a pPG612 vector and electrically transforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucoprotein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammation pathway and regulate an intestinal flora structure, so that intestinal injury and systemic inflammatory response caused by salmonella are effectively relieved. The invention provides a strain basis and technical support for developing a novel oral microecological preparation.

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The invention belongs to the technical field of cosmetics or skin injury repair preparations, and discloses application of cistanche deserticola polysaccharide in preparation of products for protecting skin barriers. The invention discloses a mechanism of the cistanche deserticola polysaccharide for protecting a skin barrier. The cistanche deserticola polysaccharide can promote proliferation of HaCaT cells and can also promote expression of tight junction proteins Claudin-1 and Occludin between the HaCaT cells; in addition, the cistanche deserticola polysaccharide has remarkable effects on preventing damage of UVB to HaCaT cells, improving the migration rate of the HaCaT cells, promoting wound healing and the like. Based on the characteristics of the cistanche polysaccharide, the cistanche polysaccharide shows huge application value in preparation of related products for protecting skin barriers.

Provided are a probiotic composition for preventing and treating intestinal inflammation and a use thereof. The probiotic composition for preventing and treating intestinal inflammation comprises a Lactobacillus acidophilus LA85 strain and a Bifidobacterium longum subsp. BL36 strain. Provided are a new probiotic formulation method and a new strategy for preventing and treating intestinal inflammation. It has been found that the LA85 strain and the BL36 strain can cooperate with each other, promote each other, have a synergistic effect in preventing and treating intestinal inflammation, can reduce the concentrations of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the serum of mice, and increase the concentration of the anti-inflammatory cytokine IL-10; can increase the concentration of urolithin A in the serum of mice and significantly reduce the concentration of reactive oxygen species in the serum; and can significantly increase the levels of the intestinal barrier indicators tight junction protein-1, tight junction protein, and Claudin-1 in the serum of mice.

The application belongs to the technical field of traditional Chinese medicine polysaccharides, and particularly relates to carboxymethylized bergamot polysaccharide as well as a preparation method and application thereof. The carboxymethylized bergamot polysaccharide prepared by the preparation method can significantly improve the mRNA expression of tight junction proteins ZO-1 and Occludin in Caco-2 cells in a lipopolysaccharide-induced Caco-2 cell inflammatory injury model, and can relieve Caco-2 cell injury and maintain the integrity of the cell barrier through a mutual transformation pathway of pentose and glucuronic acid.

The invention discloses application of ursolic acid or ursolic acid derivatives in preparation of chicken coccidiosis-resistant feed or chicken coccidiosis-resistant drugs, and relates to the technical field of biological medicines. The chicken coccidiosis protozoon is chicken eimeria tenella, the ursolic acid derivative is oleanolic acid, and the ursolic acid derivative and ursolic acid are isomers. The chicken coccidiosis-resistant feed or the chicken coccidiosis-resistant drug has at least one of the following functions: reducing the cecum lesion value and the number of oocysts, and inhibiting the depth increase of crypts induced by chicken coccidiosis; weight loss caused by chicken coccidiosis infection is relieved; the expression of inflammatory factors caused by chicken coccidiosis infection is reduced, and the inflammatory factors comprise IL-6, IL-8, TNF-alpha and IFN-gamma; the expression of tight junction protein after chicken coccidiosis infection is promoted, and the tight junction protein comprises ZO-1, Claudin-1 and Occludin. The traditional Chinese medicine composition has the advantages of low toxicity, low residue, good anti-chicken coccidiosis effect, simplicity in preparation, suitability for batch production and the like.

The invention discloses application of compound tung leaf burn oil in preparation of a medicine for treating colitis. The compound tung leaf burn oil disclosed by the invention can show the effect of improving ulcerative colitis (UC) only when the compound tung leaf burn oil is used as an active substance independently or together with other medicine components. The compound tung leaf burn oil not only can up-regulate the expression of tight junction proteins ZO-1, Occludin and Claudin-1 in the intestinal tract and maintain the integrity of the barrier, but also can down-regulate the expression of proinflammatory mediators such as TNF-alpha, TLR4 and IL-18 in serum and improve the expression level of an anti-inflammatory factor IL-4, so that the inflammation of the intestinal tract and the organism is relieved, and the barrier function of the intestinal tract is effectively repaired. In addition, the compound tung leaf burn oil can also effectively relieve intestinal flora disorder caused by DSS and maintain the intestinal steady state.

The invention discloses a composition for improving ackermann abundance and inhibiting tumor growth and application, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of pinellia ternate or 5-15 parts of hawthorn, 10-20 parts of pericarpium citri reticulatae, 5-15 parts of poria cocos, 2-11 parts of honey-fried licorice root, 2-11 parts of ginger and 2-11 parts of dark plum. The composition provided by the invention affects the intestinal flora structure and improves the abundance of Ackerman bacteria in the intestinal tract; the number of goblet cells and the expression of intestinal tight junction proteins ZO-1 and Occludin are increased, and the barrier function of the intestinal tract is improved; the number of CD8 < + > T cells and GZMB < + > cells in a tumor microenvironment is increased, and the effect of inhibiting tumor growth is achieved.

The present invention discloses the application of Hamaudol in improving acute kidney injury and intestinal barrier function, and belongs to the field of drug development technology. The present invention finds that by intraperitoneally injecting the Chinese medicine monomer Hamaudol into mice, the intestinal barrier function can be significantly improved, the expression of tight junction proteins ZO-1 and Occludin in the intestinal tract of mice can be increased, and the serological indicators of acute kidney injury can be reduced at the same time, the pathological changes of renal tubular epithelial cells in mice with acute kidney injury can be improved, the expression of inflammatory factors in the kidney can be downregulated, and apoptosis and oxidative damage can be improved. Thus, acute kidney injury is prevented and treated, and a new target is provided for the treatment of acute kidney injury.

The application discloses an albumin postbiotic peptide and application thereof in preparation of a medicine for relieving or treating food allergy, and belongs to the technical field of bioactive peptides. The albumin postbiotic peptide is prepared from egg white protein powder through enzymolysis, inoculation of fermentation lactobacillus mucus IOB802, fermentation and inactivation again. The polysaccharide content in the albumin postbiotic peptide is as high as 1860.74 mg / 100g, the albumin postbiotic peptide can regulate immune balance, reduce allergy-related factors such as IgE and IL-4 and histamine level, increase IgG2a antibody level, reduce infiltration of eosinophils and mast cells in jejunum tissue, down-regulate expression of proinflammatory factors such as IL-25 and TSLP, up-regulate tight junction proteins such as ZO-1 and Occludin, repair intestinal barrier, block penetration of allergens and relieve food allergy symptoms.

The application discloses a recombinant lactobacillus casei expressing sialyltransferase ST6GALNAC1, and belongs to the field of genetic engineering and microbial technology. The recombinant bacterium is obtained by cloning the ST6GALNAC1 gene into a pPG612 vector and electrotransforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucus protein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammatory pathway, and regulate intestinal flora structure, thereby effectively relieving intestinal injury and systemic inflammatory response caused by salmonella. The application provides a strain basis and technical support for development of a new type of oral microecological preparation.

The invention relates to the technical field of natural medicine application, and discloses a maggot fatty acid active ingredient composition and application thereof, and a high-purity fatty acid composition with a specific ingredient spectrum is obtained through an optimized supercritical CO2 extraction and molecular distillation combined technology. The composition is proved to be capable of treating UC through a multi-target and multi-channel synergistic effect for the first time: proinflammatory factors are reduced by inhibiting classical inflammatory pathways such as NF-kappa B, oxidative stress is relieved by activating an Nrf2 / HO-1 antioxidant pathway, expression of intestinal tight junction proteins (such as ZO-1 and Occludin) is specifically up-regulated so as to repair an intestinal mechanical barrier, and the UC treatment effect is improved. Meanwhile, the metabolism of short-chain fatty acid of intestinal flora is regulated so as to improve the microecology of the intestinal tract. Animal experiments show that the curative effect of the composition is superior to that of a positive drug 5-ASA, the side effect is small, and a brand-new solution derived from natural drugs is provided for solving the UC treatment dilemma.

The invention belongs to the technical field of microorganisms, and discloses a preparation method of synbiotics-loaded pH-responsive emulsion beads and application of the synbiotics-loaded pH-responsive emulsion beads in targeted improvement of colitis. Taking a mixed solution of activated and cultured probiotic bacterial sludge and fructo-oligosaccharide as a W1 phase; mixing the W1 phase with the oil phase, shearing and homogenizing to obtain a W1 / O emulsion; dispersing into a W2-phase aqueous solution dissolved with polysaccharide-protein mixed nanoparticles, and shearing and homogenizing to obtain a W1 / O / W2 dual emulsion; and cross-linking the double emulsion with polylysine, adding a sodium alginate solution, and then dropwise adding into a calcium chloride solution for curing to obtain the emulsion condensate beads. The synbiotics are loaded in the emulsion gel beads, so that the emulsion gel beads have excellent biocompatibility, enzyme triggering property and pH responsiveness. Experiments show that the emulsion gel beads improve the UC model rat colon shortening, repair the intestinal mucosa barrier, reduce the content of inflammatory factors IL-1beta, IL-6 and TNF-alpha, increase the content of an anti-inflammatory factor IL-10, increase the expression of tight junction proteins ZO-1, Claudin-1 and Occludin and regulate the intestinal flora balance of rats through synergistic interaction.

The invention belongs to the technical field of biology and bioinformatics, and particularly relates to wheat oligopeptide with anti-inflammatory and anti-oxidation activity as well as engineering bacteria and a screening method of the wheat oligopeptide. The invention provides two peptide fragments RLSYQFPFYP and KCENEECTFP which are derived from wheat oligopeptides and have anti-inflammatory and antioxidant activity, and also provides a construction method of engineering bacteria capable of expressing the peptide fragments and a method for rapidly screening the peptide fragments from functional proteins. Experiments prove that the RLSYQFPFYP can relieve the reduction of the mRNA expression level of CaSR / RAC / PLC gamma1 caused by H2O2, improve the protein expression of Occludin and Claudin-1, and reduce the apoptosis of cells; the KCENEECTFP can relieve the reduction of the mRNA expression level of Nrf2 caused by H2O2, and reduce the expression of inflammatory factors TNF-alpha and IL-8; the provided engineering bacteria can be used as a safe and large-scale active peptide production platform; the provided method for rapidly screening the peptide fragment from the functional protein can be used as a universal functional peptide rapid screening normal form, and a replicable and extensible technical framework is provided for discovery of novel peptide molecules with different physiological functions.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

To provide a hyaluronan synthase 3 (HAS3) mRNA expression promoter with excellent action effect, to provide a serine palmitoyltransferase (SPT) mRNA expression promoter, to provide an aquaporin 3 (AQP3) mRNA expression promoter, to provide a claudin-1 mRNA expression promoter, to provide a claudin-4 mRNA expression promoter, and to provide an occludin mRNA expression promoter.SOLUTION: The present invention provides a hyaluronan synthase 3 (HAS3) mRNA expression promoter, a serine palmitoyltransferase (SPT) mRNA expression promoter, an aquaporin 3 (AQP3) mRNA expression promoter, a claudin-1 mRNA expression promoter, a claudin-4 mRNA expression promoter and an occludin mRNA expression promoter, each of which contains as an active ingredient one or more selected from the group consisting of cytosine, trimethylglycine, glucuronic acid, citric acid, nicotinamide, cytidine, 3-hydroxybutyric acid, glyceric acid, and uridine.SELECTED DRAWING: None

The application belongs to the field of biological medicine, and particularly relates to application of an extract of Pteronura dumerelli in preparation of a medicine for treating ulcerative colitis, and aims to solve the technical problems of weak mucosa repair capacity, high recurrence rate after drug withdrawal, prominent long-term application safety problem, poor drug response or drug resistance of part of patients, and poor economic accessibility of existing ulcerative colitis treatment medicines. The preparation of the extract comprises the following steps: edible soft tissues of Pteronura dumerelli are washed with clean water to remove impurities, and then subjected to tissue crushing and homogenization treatment in a preset low-temperature environment; a compound enzyme system composed of neutral protease and papain is added to perform mild limited enzymolysis, and active small-molecule peptides and polysaccharide components are reserved; after low-temperature centrifugation to remove precipitates, two-stage ultrafiltration membranes are used for grading purification, high-activity small-molecule anti-inflammatory repair components are enriched, and finally low-temperature vacuum concentration and sterile filtration are performed to obtain a light yellow water-soluble active extract. The extract can inhibit activation of a nuclear factor kappa B inflammatory pathway, down-regulate levels of tumor necrosis factor alpha, interleukin 6 and interleukin 1 beta proinflammatory factors, reduce intestinal inflammatory cascade reaction, up-regulate expression of tight junction proteins Occludin and Claudin-1, repair damaged intestinal epithelial barrier, promote ulcer mucosa regeneration and healing, and realize a double synergistic treatment effect of anti-inflammation and mucosa repair.

The application discloses a strain of salivary lactobacillus and application of exopolysaccharide produced by the strain in relieving colitis, and belongs to the technical field of microorganisms and the technical field of medicines. The salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 provided by the application can efficiently produce exopolysaccharide, and the yield is 185.6 mg / L. After the exopolysaccharide of the salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 provided by the application is used on colitis mice, the colitis symptoms of the mice can be significantly relieved, which is specifically reflected in the following aspects: the disease activity score index is significantly reduced, the weight loss is relieved, the colonic histopathology is relieved, the levels of proinflammatory factors TNF-alpha, IL-1beta, IL-6, INF-gamma and IL-17 are reduced, the level of anti-inflammatory factor IL-10 is increased, and the mRNA expression amounts of tight junction proteins ZO-1 and occludin are increased. Therefore, the exopolysaccharide of the salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 has great application prospect in the preparation of products for preventing and / or treating colitis.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The invention provides an application of fructus psoraleae polysaccharide in preparation of a medicine or health food for regulating an intestinal barrier function. Specifically, the fructus psoraleae polysaccharide acts on an intestinal tract. In the intestinal tract action process, the fructus psoraleae polysaccharide effectively improves damaged intestinal tract barrier repair; the number of CD4 + and CD8 + T cells in intestinal tracts is increased, and the immune barrier of the intestinal tracts is improved; according to the present invention, the expression of tight junction proteins Claudin-1, Occludin and ZO-1 can be promoted, the intestinal mechanical barrier can be repaired and enhanced, and the polypeptide can be used for preventing, relieving or treating intestinal barrier damage, has excellent performance in the regulation of the intestinal barrier function, and has good application prospects.

The invention relates to an application of probiotics, and provides an application of clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone, and particularly relates to an application of the clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone. The formulation can be an orally administered formulation, and the viable bacteria can be dispersed in an aqueous carrier to form a solution or suspension. Animal model experiments show that the clostridium butyricum treatment can reduce kidney crystal or calcium salt deposition related characterization, reduce serum creatinine and urea nitrogen, regulate intestinal flora structure, improve expression of ileum tight junction protein ZO-1 and occludin, reduce serum endotoxin level and reduce the content of glycohyodeoxycholic acid in excrement, serum and kidney, and can be used for treating the kidney and the kidney. A novel preparation application is provided for preventing and treating the calcium oxalate kidney stone.

The invention discloses a lactobacillus johnsonii YS my4 strain with a cryptosporidium infection resisting effect and application of the lactobacillus johnsonii YS my4 strain. The preservation number of the YS my4 strain is CCTCC (China Center For Type Culture Collection) M 20253011. The strain disclosed by the invention has the characteristics of cholate resistance, intestinal juice resistance, strong adhesiveness and capability of inhibiting salmonella and staphylococcus aureus. In addition, the strain has no hemolytic rings, and the strain has no influence on body indexes and can increase the body weight after gavage of suckling rats, so that the strain is proved to be high in safety and can be applied to the fields of medicine and food. According to the invention, the YS my4 strain is intragastrically fed to a pseudo-sterile suckling mouse infected by cryptosporidium parvum, and it is found that the strain can activate immune defense of the intestinal tract of a host by improving the MAPK phosphorylation level of the host in the state of cryptosporidium parvum infection, so that the insect loading amount of the cryptosporidium parvum is remarkably reduced; meanwhile, the YS my4 strain can improve the expression level of tight junction proteins Occludin and CLDN4, relieve pathological damage of ileum tissues and improve the intestinal barrier function, and has important application value in prevention and treatment of cryptosporidium parvum infection.

The present invention provides a composition for improving the epidermal junction layer and its application. It was found that the combination of a symbiotic fermentation product of Thermus thermophilus and Bacillus sp. and grape seed extract synergistically improves the expression of proteins associated with the epidermal junction layer, increasing the expression of occludin by 316%, heparan sulfate proteoglycan (HSPG) by 64%, and hyaluronic acid receptor protein (CD44) by 69%. Compared with single ingredients, this composition is more effective in improving the health of the epidermal junction layer. It can be used to prepare cosmetics to meet the urgent need for anti-aging, has good application prospects, and also provides a new approach to the development of traditional anti-aging skin care products.

The invention belongs to the field of agricultural microbe application, and particularly relates to an application of spirillum camarum CLA-AA-M04 in resisting pseudorabies virus infection. The trichospirillum is an anaerobic neutrophile bacterium and has a gram positive ultrastructure. The verification shows that the strain plays an antiviral role through the mechanisms of improving the respiratory tract barrier function, inhibiting virus replication, reducing inflammatory response and the like. By drenching the helispirillum caffei CLA-AA-M04, the virus load of the lung and brain of the PRV infected mouse can be obviously reduced, the survival rate is improved, the pathological injury of the lung is relieved, and the expression of inflammatory factors TNF-alpha and IL-6 is inhibited. In addition, the bacterial strain repairs the epithelial barrier function of the respiratory tract by up-regulating the expression of tight connection molecules, ZO-1 and Occludin and the expression of adhesion connection molecules E-cadherin and beta-catenin. The strain can be applied to preparation of a microbial preparation for resisting pseudorabies virus infection.

The invention belongs to the technical field of biological medicine, and particularly relates to a composition containing salty taste enhancing peptide and naringenin and application of the composition. The active ingredients of the composition are composed of salty taste enhancing peptide and naringenin in a mass ratio of 100: 1. Animal experiment results show that the composition can effectively improve intestinal flora imbalance of senescence diabetes model mice, up-regulate expression of tight junction proteins ZO-1 and Occludin, repair intestinal barriers, increase the ratio of mycophylum to bacteroides, promote growth of beneficial bacteria such as micrococcus verrucosus and actinomycetes, especially promote growth of Ackerman's bacteria and bifidobacteria, and improve the immunity of senescence diabetes mellitus mice. The intestinal flora structure deviation is reversed, and the content of short-chain fatty acid in the intestinal tract is remarkably increased. The invention provides a novel prebiotic for regulating intestinal flora, and has a good application prospect.

The present invention relates to the use of OPO structured lipids in the preparation of a drug for preventing or improving intestinal epithelial barrier damage. The present invention discovers that OPO structured lipids can improve colonic epithelial barrier damage by promoting the proliferation of intestinal stem progenitor cells and the secretion of goblet cell mucin, increasing the protein expression of tight junction proteins ZO-1, Occludin, and Claudin-1, and inhibiting apoptosis of colonic epithelial cells.